Alto Neuroscience, Inc. (ANRO) Balance Sheet
As of 2026-06-30 (10-Q), Alto Neuroscience, Inc. (ANRO) reported total assets of $254.1M, total liabilities of $34.8M and shareholders' equity of $219.2M, according to EquiReason's reading of its SEC filings. Cash and equivalents: $243.7M. Long-term debt: $12.4M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ANROAlto Neuroscience, Inc.Follow ANRO — free
—
Price chart with a free account
- Market cap
- 862.1M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
| Line | FY2024 Dec 24 | FY2025 Dec 25 | Latest Jun 26 | Trend |
|---|---|---|---|---|
| Cash and equivalents | 168.2 | 176.5 | 243.7 | |
| Current assets | 169.3 | 177.7 | 247.3 | |
| Total assets | 177.5 | 184.7 | 254.1 | |
| Current liabilities | 10.0 | 11.3 | 16.7 | |
| Long-term debt | 10.3 | 16.2 | 12.4 | |
| Short-term debt | 0.0 | 0.6 | 3.8 | |
| Total liabilities | 26.1 | 33.5 | 34.8 | |
| Shareholders' equity | 151.5 | 151.1 | 219.2 |
USD millions · SEC XBRL
Alto Neuroscience, Inc. — questions
- How much cash does Alto Neuroscience, Inc. have?
- $243.7M in cash and cash equivalents as of 2026-06-30.
- How much debt does Alto Neuroscience, Inc. have?
- $12.4M of long-term debt and $3.8M due within a year as of 2026-06-30.
- What are Alto Neuroscience, Inc.'s total assets?
- $254.1M as of 2026-06-30.
- What is Alto Neuroscience, Inc.'s shareholders' equity?
- $219.2M as of 2026-06-30.
Every figure on this page comes from Alto Neuroscience, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.